Who are Buprenorphine (Subutex)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Subutex, Subutex, PBO-N/PBO-B.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/buprenorphine-subutex.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Buprenorphine (Subutex) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Buprenorphine (Subutex) (Buprenorphine (Subutex)) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Partial opioid agonist. Area: Psychiatry / Addiction Medicine.

marketed Partial opioid agonist Mu-opioid receptor (μ-OR) Psychiatry / Addiction Medicine Small molecule Live · refreshed every 30 min

Target snapshot

Buprenorphine (Subutex) (Buprenorphine (Subutex)) — Indivior Inc.. Buprenorphine is a partial opioid agonist that binds to mu-opioid receptors in the brain, reducing cravings and withdrawal symptoms while producing a lower risk of overdose compared to full opioid agonists.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Buprenorphine (Subutex) TARGET	Buprenorphine (Subutex)	Indivior Inc.	marketed	Partial opioid agonist	Mu-opioid receptor (μ-OR)
Subutex	Buprenorphine Hydrochloride	Indivior	marketed	partial opioid agonist	mu-opioid receptor, kappa-opioid receptor	1981-01-01
Subutex	BUPRENORPHINE	Purdue Pharma Lp	marketed	Partial Opioid Agonist	mu-opioid receptor, kappa-opioid receptor	1981-01-01
PBO-N/PBO-B	PBO-N/PBO-B	Alkermes, Inc.	phase 3	partial opioid agonist	mu-opioid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-07-31 — Subutex · 8236755 · Formulation · US
2027-01-10 — Subutex · 8236292 · Formulation · US
2027-07-23 — Subutex · 8147866 · Formulation · US
2027-07-23 — Subutex · 9655843 · Formulation · US
2031-06-06 — Subutex · 9782402 · Formulation · US
2031-06-06 — Subutex · 9827241 · Formulation · US
2031-06-06 — Subutex · 10198218 · Method of Use · US
2031-06-06 — Subutex · 10592168 · Method of Use · US
2031-06-06 — Subutex · 9498432 · Formulation · US
2031-06-06 — Subutex · 9272044 · Method of Use · US
2031-06-25 — Subutex · 10558394 · Formulation · US
2031-09-05 — Subutex · 8975270 · Formulation · US
2032-01-06 — Subutex · 8921387 · Formulation · US
2032-07-26 — Subutex · 11135215 · Formulation · US
2032-07-26 — Subutex · 12318379 · Formulation · US
2032-07-26 — Subutex · 12161640 · Formulation · US
2032-07-26 — Subutex · 11110084 · Formulation · US
2032-07-26 — Subutex · 10912772 · Method of Use · US
2032-07-26 — Subutex · 9937164 · Formulation · US
2032-12-21 — Subutex · 9901539 · Method of Use · US
2035-11-06 — Subutex · 11000520 · Method of Use · US
2035-11-06 — Subutex · 11839611 · Method of Use · US
2038-06-22 — Subutex · 10646484 · Method of Use · US

Sponsor landscape (Partial opioid agonist class)

Indivior Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Buprenorphine (Subutex) — Competitive Intelligence Brief. https://druglandscape.com/ci/buprenorphine-subutex. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing